Tirasemtiv
As of the edition of 20 October 2026, Tirasemtiv is a small molecule: went quiet in 2018; acts on TNNC2, TNNI2 and TNNT3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2018
- Kind
- Small molecule
- Registered trials
- 8, 1 stopped early
- Disease areas
- Nervous system; Nutrition and metabolism; Cancer; Heart and blood vessels; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 6 | 5 | 0 | 1 |
| Phase 3 | 2 | 2 | 0 | 0 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Cytokinetics | Lead sponsor of trials | 2010 to now |